GlassScriptPhysician profile
Deanna L Edwards
NPI 1851406912
$1,861.16
in general payments reported to CMS, 2019-2025
31 companies · $222 in 2025
The $222 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2021: $315 · 2022: $219 · 2023: $440 · 2024: $446 · 2025: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,108.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $483.82 | 2019-2024 | Qulipta, Ubrelvy, Vraylar |
| Pfizer INC. | $147.43 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $132.60 | 2023-2024 | |
| Boston Scientific Corporation | $125.56 | 2022-2025 | Watchman Flx, Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.73 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Lilly USA, LLC | $89.20 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Amarin Pharma, INC. | $73.25 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $69.32 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $68.08 | 2021-2024 | |
| Amgen INC. | $64.45 | 2019-2023 | Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $49.60 | 2019-2025 | Breztri |
| Otsuka America Pharmaceutical, INC. | $45.40 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.33 | 2023-2024 | Xifaxan |
| Novo Nordisk INC | $39.69 | 2021-2023 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $37.31 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $36.19 | 2019 | |
| Xeris Pharmaceuticals, INC. | $33.32 | 2023-2025 | Gvoke Hypopen, Keveyis |
| Ascensia Diabetes Care US INC. | $31.99 | 2024-2025 | |
| Astellas Pharma US INC | $28.26 | 2019 | |
| Sumitomo Pharma America, INC. | $20.23 | 2025 | Gemtesa |
| Ardelyx, INC. | $19.55 | 2024 | Ibsrela |
| Philips North America LLC | $18.05 | 2023 | |
| Abbott Laboratories | $17.41 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.13 | 2024 | Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $14.68 | 2021 | |
| Kyowa Kirin, INC. | $13.41 | 2023 | Crysvita |
| Biohaven Pharmaceuticals, INC. | $13.00 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.25 | 2022 | |
| Glaxosmithkline, LLC. | $10.97 | 2019 | |
| Organon LLC | $8.68 | 2022 | |
| Phathom Pharmaceuticals, INC. | $7.27 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deanna Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.